ReviewOncogene2002
The study of aberrant methylation in cancer via restriction landmark genomic scanning.
Review in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Bioinformatics analysis of TRPV1 expression and its role in hepatocellular carcinoma prognosis.Discover oncology · 2026Article
- ACBD3 Bioinformatic Analysis and Protein Expression in Breast Cancer Cells.International journal of molecular sciences · 2022Article
- Association between HIC1 promoter methylation and solid tumor: A meta-analysis.EXCLI journal · 2020Article
- Strategies for discovery and validation of methylated and hydroxymethylated DNA biomarkers.Cancer medicine · 2012Review
- DNA methylation in promoter region as biomarkers in prostate cancer.Methods in molecular biology (Clifton, N.J.) · 2012Article
- Genome-wide epigenetic modifications in cancer.Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques · 2011Review
- A proof-of-principle demonstration of a novel microarray-based method for quantifying DNA methylation levels.Molecular biotechnology · 2010Article
- Promoter hypermethylation in prostate cancer.Cancer control : journal of the Moffitt Cancer Center · 2010Review
- DNA methylation changes in a human cell model of breast cancer progression.Mutation research · 2010Article
- Estrogen and xenoestrogens in breast cancer.Toxicologic pathology · 2010Review
- DNA methylation of cancer genome.Birth defects research. Part C, Embryo today : reviews · 2009Review
- Methods in DNA methylation profiling.Epigenomics · 2009Review
- A novel role for mitochondria in regulating epigenetic modification in the nucleus.Cancer biology & therapy · 2008Article
- Review
- Phenotype-specific CpG island methylation events in a murine model of prostate cancer.Cancer research · 2008Article
- Structures of the rare-cutting restriction endonuclease NotI reveal a unique metal binding fold involved in DNA binding.Structure (London, England : 1993) · 2008Article
- DNA methylation, insulin resistance, and blood pressure in offspring determined by maternal periconceptional B vitamin and methionine status.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability.PloS one · 2007Article
- Familial molar tissues due to mutations in the inflammatory gene, NALP7, have normal postzygotic DNA methylation.Human genetics · 2006Article
- Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas.Oncogene · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Restriction landmark genomic scanning (RLGS) has been used to study DNA methylation in cancer for nearly a decade. The strong bias of RLGS for assessing the methylation state of CpG islands genome wide makes this an attractive technique to study both hypo- and hypermethylation of regions of the genome likely to harbor genes. RLGS has been used successfully to identify regions of hypomethylation, candidate tumor suppressor genes, correlations between hypermethylation events and clinical factors, and quantification of hypermethylation in a multitude of malignancies. This review will examine the major uses of RLGS in the study of aberrant methylation in cancer and discuss the significance of some of the findings.
Indexed as
Identifiers
12154404What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.